- -

Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients.

RiuNet: Institutional repository of the Polithecnic University of Valencia

Share/Send to

Cited by

Statistics

Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients.

Show simple item record

Files in this item

dc.contributor.author Sirera Pérez, Rafael es_ES
dc.date.accessioned 2016-06-01T11:57:50Z
dc.date.available 2016-06-01T11:57:50Z
dc.date.issued 2011-07
dc.identifier.issn 1525-7304
dc.identifier.uri http://hdl.handle.net/10251/65057
dc.description.abstract [EN] Background: Platinum doublets are standard chemotherapy for advanced non-small-cell lung cancer (NSCLC). The aim of this study was to assess whether neutropenia is: (1) an indicator for treatment efficacy, or (2) associated with specific polymorphisms. Patients and Methods: Four hundred ninety-four patients, treated with cisplatin-docetaxel were retrospectively analyzed. Relative dose intensity (RDI) was assessed for both drugs. Neutrophil counts were assessed only on Day 21 of each cycle. Genotyping was performed for 4 different polymorphisms in ERCC1, XRCC3, XPD-23, and XPD-10. Results: The median overall survival was 9 months. The mean RDI was 0.94 for cisplatin and 0.93 for docetaxel. Four hundred three patients received ¿ 3 cycles of chemotherapy, and 239 received ¿ 6 cycles. Thirty-one percent developed neutropenia, and 19% had Grade (G)3-4 neutropenia. RDI was lower in patients with neutropenia (G1-4; 0.87-0.93) when compared with those without (G0; 0.94-0.95; P <.02). Male patients (P =.02) had inferior survival when compared with female patients, and ECOG (Eastern Cooperative Oncology Group) 1-2 patients (P <.001) had worse survival when compared with ECOG 0. There was no significant survival difference with respect to Grade of neutropenia (G0, 8.7 vs. G1-2, 11.6 vs. G3-4, 9.6 months; P =.41). In ECOG 0 patients, survival was significantly better for neutropenic G1-4 (hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.31-0.96; P =.034) when compared with non-neutropenic (G0) patients. No association was observed between examined polymorphisms and neutropenia. Conclusion: RDI was significantly higher in patients who did not develop neutropenia during treatment, but as the nadir period was not explored in our study, the low occurrence of neutropenia in our cohort is considered underestimated. There was no significant survival difference with respect to grade of neutropenia. Finally, none of the examined single nucleotide polymorphisms (SNPs) were associated with the presence of neutropenia, disease characteristics, response rates, or survival. © 2011 Elsevier Inc. All rights reserved. es_ES
dc.language Inglés es_ES
dc.publisher Elsevier es_ES
dc.relation.ispartof Clinical Lung Cancer es_ES
dc.rights Reserva de todos los derechos es_ES
dc.subject Advanced disease es_ES
dc.subject Chemotherapy es_ES
dc.subject Efficacy to therapy es_ES
dc.subject NSCLC es_ES
dc.subject SNP es_ES
dc.subject Cisplatin es_ES
dc.subject Docetaxel es_ES
dc.subject Excision repair cross complementing protein 1 es_ES
dc.subject Unclassified drug es_ES
dc.subject Xeroderma pigmentosum group D protein es_ES
dc.subject Xeroderma pigmentosum group D protein 10 es_ES
dc.subject Xeroderma pigmentosum group D protein 23 es_ES
dc.subject XRCC3 protein es_ES
dc.subject Advanced cancer es_ES
dc.subject Article es_ES
dc.subject Cancer combination chemotherapy es_ES
dc.subject Chemotherapy induced neutropenia es_ES
dc.subject DNA repair es_ES
dc.subject Drug dose reduction es_ES
dc.subject Drug dose regimen es_ES
dc.subject Drug efficacy es_ES
dc.subject Drug induced disease es_ES
dc.subject Gene frequency es_ES
dc.subject Human es_ES
dc.subject Lung non small cell cancer es_ES
dc.subject Multiple cycle treatment es_ES
dc.subject Neutropenia es_ES
dc.subject Overall survival es_ES
dc.subject Prognosis es_ES
dc.subject Sex difference es_ES
dc.subject Single nucleotide polymorphism es_ES
dc.subject Treatment response es_ES
dc.subject Adenocarcinoma es_ES
dc.subject Adult es_ES
dc.subject Aged es_ES
dc.subject Antineoplastic Combined Chemotherapy Protocols es_ES
dc.subject Carcinoma, Large Cell es_ES
dc.subject Carcinoma, Non-Small-Cell Lung es_ES
dc.subject Carcinoma, Squamous Cell es_ES
dc.subject DNA-Binding Proteins es_ES
dc.subject Endonucleases es_ES
dc.subject Female es_ES
dc.subject Follow-Up Studies es_ES
dc.subject Humans es_ES
dc.subject Lung Neoplasms es_ES
dc.subject Male es_ES
dc.subject Middle Aged es_ES
dc.subject Neoplasm Staging es_ES
dc.subject Polymorphism, Genetic es_ES
dc.subject Retrospective Studies es_ES
dc.subject Survival Rate es_ES
dc.subject Taxoids es_ES
dc.subject Treatment Outcome es_ES
dc.subject.classification MICROBIOLOGIA es_ES
dc.title Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients. es_ES
dc.type Artículo es_ES
dc.identifier.doi 10.1016/j.cllc.2011.03.023
dc.rights.accessRights Cerrado es_ES
dc.contributor.affiliation Universitat Politècnica de València. Departamento de Biotecnología - Departament de Biotecnologia es_ES
dc.description.bibliographicCitation Sirera Pérez, R. (2011). Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients. Clinical Lung Cancer. 12(4):224-230. doi:10.1016/j.cllc.2011.03.023 es_ES
dc.description.accrualMethod Senia es_ES
dc.relation.publisherversion https://dx.doi.org/10.1016/j.cllc.2011.03.023 es_ES
dc.description.upvformatpinicio 224 es_ES
dc.description.upvformatpfin 230 es_ES
dc.type.version info:eu-repo/semantics/publishedVersion es_ES
dc.description.volume 12 es_ES
dc.description.issue 4 es_ES
dc.relation.senia 220988 es_ES


This item appears in the following Collection(s)

Show simple item record